SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
| Thursday, May 9th @ 4:30 PM ET | |
| Domestic: | 1-888-886-7786 |
| International: | 1-416-764-8658 |
| Conference ID: | 71864759 |
Participants can use Guest dial-in #s above and be answered by an operator OR click the Call me™ link for instant telephone access to the event.
Call me™: https://emportal.ink/3xjDV8X
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1664624&tp_key=4756f5f4c0
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, first-in-class, oral ACTH antagonist, that is currently in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the Company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.
Contact:
Corey Davis
LifeSci Advisors, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
(212) 915-2577
Media:
Natalie Badillo
Head of Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
858 345-6075
| Last Trade: | US$34.47 |
| Daily Change: | -0.57 -1.63 |
| Daily Volume: | 1,294,433 |
| Market Cap: | US$3.200B |
February 27, 2025 January 10, 2025 December 09, 2024 November 12, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
